Hi guys, Welcome to the Advanced Video Search Engine, and you are watching Expert report on survival data from pivotal trials with PARP inhibitors for BRCA-mut. Ovarian Cancer. That video is uploaded by European Society for Medical Oncology (ESMO) at 2022-09-20T08:38:45-07:00. We are promoting this video only for entertainment and educational purpose only. So, I hope you like & enjoy it. [0lNuVh8BtEU]
| Name | Expert report on survival data from pivotal trials with PARP inhibitors for BRCA-mut. Ovarian Cancer |
| Video Uploader | Video From European Society for Medical Oncology (ESMO) |
| Upload Date | This Video Uploaded At 20-09-2022 15:38:45 |
| Video Discription | Isabelle Ray-Coquard discusses abstracts presented at ESMO Congress 2022: - LBA29: Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) - 517O: Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial - 518O: Overall survival results from ARIEL4: a phase 3 study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation Produced by the European Society for Medical Oncology http://oncologypro.esmo.org This video was supported with an unrestricted grant from Bayer Healthcare. The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO. 0lNuVh8BtEU |
| Category | Science & Technology |
| Tags | ESMO | ESMO Congress 2022 | #ESMO22 | PARP inhibitors | Ovarian cancer | BRCA-mutated | ARIEL4 | PAOLA-1/ENGOT-ov25 | SOLO1/GOG-3004 | olaparib | rucaparib |
